** Shares of drug distributor Cencora COR.N rise 1.7% to $255.77
** Co raises fiscal 2025 profit forecast, driven by robust demand for expensive specialty medicines
** Expects 2025 adj. profit to range between $15.25 and $15.55 per share, up from previous view of $15.15 to $15.45
** Reports adj. Q1 profit of 3.73 per share, beating estimates of $3.50 per share - data compiled by LSEG
** Q1 sales in its U.S. healthcare solutions segment rose 13.6% to $74.0 billion
** "COR is off to a strong year stock-wise, but we see this quarter/guidance as another reason to see further upside on both estimates and multiple expansion," brokerage Leerink Partners says
** Stock rose 9.4% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。